<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855045</url>
  </required_header>
  <id_info>
    <org_study_id>PQ-110-005</org_study_id>
    <nct_id>NCT04855045</nct_id>
  </id_info>
  <brief_title>An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (&lt;8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.</brief_title>
  <acronym>BRIGHTEN</acronym>
  <official_title>An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects &lt;8 Years of Age With Leber Congenital Amaurosis Type 10 (LCA10) Due to the c.2991 +1655A&gt;G (p.Cys998X) Mutation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProQR Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProQR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PQ-110-005 (BRIGHTEN) is an open-label, dose escalation and double-masked, randomized,&#xD;
      controlled study evaluating safety and tolerability of sepofarsen administered via&#xD;
      intravitreal (IVT) injection in pediatric subjects (&lt;8 years of age) with LCA10 due to the&#xD;
      c.2991+1655A&gt;G mutation over 24 months of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, dose escalation and double-masked, randomized, controlled study&#xD;
      evaluating safety and tolerability of sepofarsen administered via intravitreal (IVT)&#xD;
      injection in pediatric subjects (&lt;8 years of age) with LCA10 due to the c.2991+1655A&gt;G&#xD;
      mutation. The study consists of two parts: an open-label dose escalation part, followed by a&#xD;
      double-masked randomized part.&#xD;
&#xD;
      In the open label part; subjects will be assigned to one of 3 planned dose groups using a&#xD;
      staggered dose escalation design. After at least 1 patient is dosed in each group; the Data&#xD;
      Monitoring Committee (DMC) will review at least 4 weeks of safety data post dosing; and may&#xD;
      recommend initiation of the next dose group. The DMC may recommend initiation of the&#xD;
      double-masked randomized part of the study after completion of the last dose group in the&#xD;
      dose escalation part of the study.&#xD;
&#xD;
      In the double-masked, randomized, controlled part of the study; subjects will be randomized&#xD;
      to one of 2 planned dose groups .&#xD;
&#xD;
      Subjects will receive a unilateral IVT injection of sepofarsen on Day 1. Thereafter a&#xD;
      6-monthly dosing schedule is planned.&#xD;
&#xD;
      After each dosing subjects will be assessed for safety and tolerability at follow up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study consists of two parts: an open-label dose escalation part, followed by a double-masked randomized part.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of ocular adverse events (AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of ocular adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of non-ocular adverse events (AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of non-ocular adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 12 in Best-corrected visual acuity (BCVA)</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change in BCVA relative to baseline after 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 12 in retinal sensitivity measured by Full-field stimulus testing (FST)</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change in retinal sensitivity measured by FST relative to baseline after 12 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Leber Congenital Amaurosis 10</condition>
  <condition>Blindness</condition>
  <condition>Leber Congenital Amaurosis</condition>
  <condition>Vision Disorders</condition>
  <condition>Sensation Disorders</condition>
  <condition>Neurologic Manifestations</condition>
  <condition>Eye Diseases</condition>
  <condition>Eye Disorders Congenital</condition>
  <condition>Retinal Disease</condition>
  <condition>Retinal Degeneration</condition>
  <condition>Retinal Dystrophies</condition>
  <arm_group>
    <arm_group_label>Group 1 - open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: double-masked, randomized to one of 2 dose cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sepofarsen</intervention_name>
    <description>RNA antisense oligonucleotide for intravitreal injection</description>
    <arm_group_label>Group 1 - open label</arm_group_label>
    <arm_group_label>Group 2 - open label</arm_group_label>
    <arm_group_label>Group 3: open label</arm_group_label>
    <arm_group_label>Group 4: double-masked, randomized to one of 2 dose cohorts</arm_group_label>
    <other_name>QR-110</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female child, &lt;8 years of age at Screening with a clinical diagnosis of LCA&#xD;
             and a molecular diagnosis of homozygosity or compound heterozygosity for the CEP290&#xD;
             p.Cys998X mutation, based on genotyping analysis at Screening. A historic genotyping&#xD;
             report from a certified laboratory are acceptable with Sponsor approval.&#xD;
&#xD;
          -  BCVA equal to or better than Logarithm of the Minimum Angle of Resolution (logMAR) +&#xD;
             4.0 (Light Perception), and equal to or worse than logMAR + 0.4 in the treatment eye.&#xD;
&#xD;
          -  Detectable outer nuclear layer (ONL) in the area of the macula.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any significant ocular or non-ocular disease/disorder which may put the&#xD;
             subject at risk because of participation in the trial' may influence the results of&#xD;
             the trial, or the subject's ability to participate in the trial.&#xD;
&#xD;
          -  Receipt within 1 month prior to Screening of any intraocular or periocular surgery&#xD;
             (including refractive surgery), or an IVT injection or planned intraocular surgery or&#xD;
             procedure during the course of the trial.&#xD;
&#xD;
          -  Current treatment or treatment within the past 12 months with therapies known to&#xD;
             influence the immune system (including but not limited to cytostatics, interferons,&#xD;
             TNF-binding proteins, drugs acting on immunophilins, or antibodies with known impact&#xD;
             on the immune system).&#xD;
&#xD;
          -  Current treatment or treatment within the past 3 months or planned treatment with&#xD;
             drugs known to be toxic to the lens, retina, or the optic nerve.&#xD;
&#xD;
          -  Use of any investigational drug or device within 3 months or 5 half-lives of Day 1,&#xD;
             whichever is longer, or plans to participate in another study of a drug or device&#xD;
             during the trial period.&#xD;
&#xD;
          -  Any prior receipt of genetic or stem-cell therapy for ocular or non-ocular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ProQR Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>ProQR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ProQR Clinical Trials Manager</last_name>
    <phone>+31881667000</phone>
    <email>info@proqr.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent (UZ)</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Leroy</last_name>
      <email>bart.leroy@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Bart Leroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig Universität - Department of Ophthalmology</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lyubomyr Lytvynchuk</last_name>
      <phone>+49-641-985-43803</phone>
      <email>lyubomyr.Lytvynchuk@augen.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Lyubomyr Lytvynchuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tübingen - Institute for Ophthalmic Research</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Rindtorff</last_name>
      <phone>+49 7071 29 87747</phone>
      <email>andrea.rindtorff@stz-eyetrial.de</email>
    </contact>
    <investigator>
      <last_name>Katarina Stingl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam University Medica Center - Locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Wezel</last_name>
      <phone>+31 205668618</phone>
      <email>m.wezel@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Camiel Boon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital - NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flora Kakanou</last_name>
      <phone>+44 0207 253 3411</phone>
      <phone_ext>2109</phone_ext>
      <email>flora.kakanou@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Michel Michaelides</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.proqr.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LCA10</keyword>
  <keyword>CEP290</keyword>
  <keyword>p.Cys998X</keyword>
  <keyword>c.2991+1655A&gt;G</keyword>
  <keyword>Leber Congenital Amaurosis</keyword>
  <keyword>Antisense oligonucleotide</keyword>
  <keyword>RNA therapy</keyword>
  <keyword>QR-110</keyword>
  <keyword>sepofarsen</keyword>
  <keyword>pediatric</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Sensation Disorders</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
    <mesh_term>Eye Abnormalities</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

